March 27, 2024

For this week's episode of The Leverage Report, we hear Dave Cate's recollection of the events that led up to the $60M NEC Verdict that he obtained for the deserving family.
To connect with Dave Cates regarding his experience or other legal questions:
Email: [email protected]
LinkedIn: https://www.linkedin.com/company/cates-law-firm-llc/
See the full transcription here: https://yourcaseworks.com/the-leverage-report/david-cates-provides-insights-to-60m-nec-verdict/

Mar 20, 2024

Welcome to this week's episode of Tort Talk Thursday with Joe Fantini! In this video, Joe gives us the latest information on:

- $60 Million NEC verdict

- Will Bayer File for Bankruptcy?

- Hair Relaxer Lawsuit Developments

- Social Media Lawsuits

How to get in contact with Joe: Email - [email protected] LinkedIn - https://www.linkedin.com/in/joseph-fantini/

See the full video transcript here: https://yourcaseworks.com/the-leverage-report/3-21-24-tort-talk-thursday/

Don't forget to subscribe and stay updated on the latest Mass Tort news!

March 13, 2024

Did you catch Ryan Stephen's Panel at LITFINCON? On our latest episode of The Leverage Report, we had the pleasure of discussing Ryan's recap of the conference and how Pine Valley Capital Partners offers secure and strategic litigation financing.
For more information, reach out to Pine Valley Capital directly at [email protected] or Ryan on LinkedIn at https://www.linkedin.com/in/ryanstephen/.

March 14, 2024

Welcome to this week's episode of Tort Talk Thursday with Joe Fantini! In this video, Joe gives us the latest information on:

March 7, 2024

Welcome to this week's episode of Tort Talk Thursday with Joe Fantini! In this video, Joe gives us the latest information on:
💧Camp Lejeune Tier 2 Cases
⚖️Recent RoundUp Trials
🗓️Upcoming CPAP Case Management Conference
📄Suboxone Filings
🚙Uber Assault Cases
How to get in contact with Joe:
Email - [email protected]
LinkedIn - https://www.linkedin.com/in/joseph-fantini/
See the full video transcript here: https://yourcaseworks.com/the-leverage-report/3-7-24-tort-talk-thursday/
🔔Don't forget to subscribe and stay in on the latest Mass Tort news!

March 14, 2024

On this episode of The Leverage Report, we hear all the details about the case management conference for Ozempic that occurred March 14th, 2024. We had the pleasure of discussing Danae Benton's recap of the conference and getting insights into how the Ozempic MDL will move forward.

To connect with Danae Benton regarding pending Ozempic lawsuits, reach out to her directly: Email: [email protected] LinkedIn: https://www.linkedin.com/in/danae-n-benton-49599340/

See the full transcription here: https://yourcaseworks.com/the-leverage-report/danae-benton-recaps-march-14th-ozempic-case-management-conference/

March 6, 2024

Bard Port Catheter MDL Litigation Update: What Plaintiffs Firms Need to Know
The multidistrict litigation over Bard's allegedly defective port catheters continues to rapidly progress, requiring close attention from plaintiffs attorneys assisting harmed patients. In Case Works’ recent podcast interview with members of the leadership team, including attorneys from Berger Montague, we discussed critical updates on this litigation expected to move swiftly to bellwether trials by late 2025.
With over 100 lawsuits consolidated in Arizona federal court, Judge David Campbell is moving this MDL forward at an aggressive pace. Leadership has been appointed, discovery is underway, and the initial bellwether pool is set. Attorneys assisting plaintiffs should closely track litigation developments to ensure their clients' rights are fully protected as we rapidly approach trial.
Interested in connecting with the attorneys of Berger Montague?
Shanon Carson: [email protected]
Jennifer Elwell: [email protected]
John Albanese: [email protected]
Or visit https://bergermontague.com/contact-us/
See the full video with transcript here: https://yourcaseworks.com/the-leverage-report/bard-powerport-cathedar-lawsuit-updates-with-berger-montague/

March 6, 2024

Ken Reimer dives deep into Case Works' Rapid Record Solution that is sure to show your true marketing ROI when it comes to validating leads!
Connect with Ken: https://yourcaseworks.com/contact/
https://yourcaseworks.com/the-leverage-report/rapid-record-solutions-enhances-roi-validated-leads/

February 29, 2024

Welcome to another episode of Tort Talk Thursday with Joe Fantini!
How to get in contact with Joe:
Email - [email protected]
LinkedIn - https://www.linkedin.com/in/joseph-fantini/
See the full video transcript here: https://yourcaseworks.com/the-leverage-report/2-26-updates-tort-talk-thursday/
🔔Don't forget to subscribe and stay in on the latest Mass Tort news!
.
.
.
During this week's episode, Attorney Joe Fantini provided a thorough update on several major ongoing mass tort lawsuits. He covered recent developments across key cases involving hernia mesh products, the Boy Scouts settlement, as well as emerging litigation around the medications Suboxone and Ozempic.
Starting with hernia mesh, Joe noted a bellwether trial is scheduled to begin next week in New Jersey state court focused on cases involving Stratus mesh. This will be a significant data point, given trials have been rare so far in the hernia mesh litigation. In addition, the federal judge overseeing the largest hernia mesh MDL against C.R. Bard, consisting of over 40,000 filed cases, has ordered the parties to mediate beginning March 3rd and 4th. After years of these cases progressing, requiring mediation is a promising indication that we could see meaningful resolution on the horizon for plaintiffs.
Regarding the Boy Scouts settlement, Joe explained the positive update that the court lifted a temporary stay blocking the settlement after an appeal from survivors seeking more time to submit claims. With the stay removed, the settlement is now moving forward once again, with the claim form deadline still set for May 31st. Assuming forms are filed in time, Joe anticipates compensation will start heading to victims of abuse later this year as the claims are evaluated and approved.
As for newly formed lawsuits, Joe provided details on both the Suboxone and Ozempic MDLs. For Suboxone, the initial case management conference is scheduled for early March before the federal judge in the Eastern District of Pennsylvania. The litigation is focused on patients who took brand name Suboxone to treat opioid addiction for over 30-90 days and subsequently experienced severe dental problems like tooth decay that required oral surgery. The key criteria is that the medication must have been taken prior to an important label change in 2022 warning of these dental risks.
At the same time, Ozempic's initial conference is slated for March 14th. The judge is taking a unique approach to get out in front of certain issues before entering any formal orders. There will be an initial meeting to discuss appointing leadership counsel, the process for case filings and discovery, as well as evaluating whether to segment or group defendants who have varying products consolidated in the MDL. Joe expects the leadership structure will be formalized before the end of spring.
In summary, it's an active period across the mass tort landscape with momentum building on major established litigation like hernia mesh while new cases quickly emerge and ramp up. We anticipate learning much more following the imminent initial conferences for Suboxone and Ozempic.

February 21, 2024

Learn more about Case Works' fee deferral solution on our website: https://yourcaseworks.com/solutions/
______________________________________________________________
The litigation financing industry has experienced explosive growth in recent years, with market size estimates projecting it will be a $20 billion industry within the next 4-5 years. This influx of capital has fundamentally changed the dynamics for law firms, allowing them to take on significantly larger case inventories than ever before. But this rapid growth also creates challenges - how can law firms fund the upfront costs associated with acquiring and developing large dockets of cases?
This is where fee deferral comes in. Fee deferral solutions allow law firms to defer paying fees for case development services until the time of settlement. Rather than paying these costs upfront, firms can redeploy that capital into acquiring even more cases. This approach unlocks substantial financial leverage and improves ROI by a staggering 40-50%.
However, not all fee deferral offerings are created equal. Many providers fund fee deferrals through their own balance sheet, taking on risk until settlement. To reduce their risk exposure, these providers often prioritize near-settlement cases while letting other cases languish untouched for years. Law firms working with these partners routinely complain of having no visibility into case progress and inactive cases.
Case Works has structured their fee deferral solution to align incentives and provide transparency for law firms. Rather than putting their own balance sheet at risk, Case Works partners with third-party litigation funders who take on the risk associated with deferred fees. This enables Case Works to work every case equally, applying the same high-touch approach regardless of where the case sits in the litigation timeline.
Law firms exploring fee deferral solutions should ask potential partners key questions, like: What other cases are you working on? How will you fund the work? Are you comfortable with pre-Daubert torts? Do you provide reporting transparency? Case Works' approach delivers the consistency, transparency, and experience law firms need to optimize fee deferral.
The exponential growth in litigation financing has unlocked substantial opportunities for law firms to scale. But realizing that potential hinges on implementing the right fee deferral solution. With the appropriate partner, fee deferral can provide law firms with a strategic lever to unlock transformative growth.